Novavax (NVAX) Stock Forecast & Price Target

Novavax is well positioned by the differentiated value of Matrix-M, a saponin-based adjuvant that has already shown broad clinical utility and appears safer and more powerful than competing approaches, creating a credible platform for future vaccine development and partnering. Its collaboration footprint has expanded to four top-ten global pharmaceutical companies and 30+ unique fields across infectious disease and oncology, while the Sanofi deal and Pfizer license support the possibility of high-value royalties in the high teens to low 20s and multiple program-level economics. The outlook is further supported by encouraging early commercial signals, including Sanofi-reported Q1:26 Nuvaxovid sales of €16MM, estimated 19% to 26% standalone market share by 2030, and management’s $200MM core-expense run-rate target.

Novavax is facing a structurally weaker U.S. COVID-19 vaccine market, with surveyed physicians expecting an 11% decline in vaccinated adults in the 2026-27 season and IQVIA Rx data already indicating about a 26% decline through 12/26/25. The company also appears constrained by tighter FDA/CDC guidelines implemented in '25 that limit access for people without risk factors, while its standalone Nuvaxovid share is still only forecast at 19% by physicians and 26% by payors in 2030. With additional downside risks tied to combo-vaccine execution, variant-specific boosters in FY25+, regulatory setbacks, and broader competitive and pricing pressure, the business case remains fragile for a clinical-stage company dependent on pipeline success and partnerships.